Protocol

PREVENT: Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Congestive Heart Failure (PREVENT-CHF):A Phase IIB Randomized Placebo-Controlled Trial

Diseases

Phase I Studies : congestive heart failure

Description

Anthracyclines are chemotherapy drugs commonly used in the treatment of many childhood cancers. High doses of anthracyclines are known to increase the risk of heart muscle weakness (cardiomyopathy) and congestive heart failure. This study is designed to measure what effect taking low-dose Carvedilol for two years might have on preventing the heart muscle changes that can lead to cardiomyopathy and congestive heart failure. Survivors of childhood cancers who received 300 mg/m2 or more of anthracyclines will be randomly (like tossing a coin) assigned to take a low dose of Carvedilol or an identical looking pill which contains no medicine (placebo).


Objectives


Eligibility

For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE (1-866-278-5833).


Contact

Melissa M. Hudson MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Voice: 1-888-226-4343 or 901-595-4055
FAX: 901-595-4011

Referring or consulting physicians only: protocolinfo@stjude.org

For all other inquiries about St. Jude Children's Research Hospital studies: info@stjude.org

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.